TB Notes Newsletter
No. 2, 2007
NEW CDC PUBLICATIONS
Andre M, Ijaz K, Tillinghast JD, Krebs VE, Diem LA,
Metchock B, Crisp T, and McElroy PD. Transmission
network analysis to complement routine tuberculosis
contact investigations. Am J Public Health 2007;97:
470-477.
Baumann MH, Nolan R, Petrini M, Lee YCG, Light RW,
and Schneider E.
Pleural tuberculosis in the United
States: incidence and drug resistance.
(PDF) Chest Apr 2007:
1125–1132.
CDC. Extensively drug-resistant tuberculosis. MMWR
2007; 56(11): 250-253.
CDC. Trends in tuberculosis incidence. MMWR 2007;
56(11): 245-250.
CDC. World TB Day – March 24, 2007 [box]. MMWR 2007;
56(11): 245.
CDC/DTBE.
Extensively Drug-Resistant Tuberculosis (XDR
TB)
- Fact sheet
2007.
CDC/DTBE.
CDC’s Role in Preventing Extensively
Drug-Resistant Tuberculosis (XDR TB)
- Fact sheet
2007.
CDC/DTBE.
Forging Partnerships to Eliminate
Tuberculosis, 2007 - Guide
and toolkit.
CDC/DTBE.
Multidrug-Resistant Tuberculosis (MDR TB)
- Fact sheet 2007.
CDC/DTBE.
The Revised Report of Verified Case of
Tuberculosis. - Fact sheet
2007.
Castro KG. Tuberculosis surveillance: data for
decision-making [editorial]. Clinical Infectious
Diseases 2007 May 15; 44: 1268-70.
Cheruvu M, Plikaytis BB, Shinnick TM. The
acid-induced operon Rv3083–Rv3089 is required for growth
of Mycobacterium tuberculosis in macrophages.
Tuberculosis 2007; 87: 12-20.
Dewan PK, Grinsdale J, Kawamura LK. Low sensitivity
of a whole-blood interferon-gamma release assay for
detection of active tuberculosis. Clinical Infectious
Diseases 2007 Jan 1; 44: 69-73.
Frieden TR, Munsiff SS, Desai Ahuja S. Outcomes of
multidrug-resistant tuberculosis treatment in
HIV-positive patients in New York City, 1990-1997
[letter]. International Journal of Tuberculosis and Lung
Disease January 2007; 11 (1): 116.
Fu LM, Shinnick TM. Understanding the action of INH
on a highly INH-resistant Mycobacterium tuberculosis
strain using Genechips. Tuberculosis 2007; 87:63-70.
Haddad MB, Diem LA, Cowan LS, Cave MD, Bettridge J,
Yun L, Winkler CS, Ingman DD, Oemig TV, Lynch A, Montero
JT, McCombs SB, Ijaz K. Tuberculosis genotyping in six
low-incidence states, 2000–2003. Am J Prev Med 2007;
32(3): 239–243.
Ijaz K, McElroy PD, Jereb J, Navin TR, Castro KG.
Safety of the rifampin and pyrazinamide short-course
regimen for treating latent tuberculosis infection
[letter]. Clinical Infectious Diseases 2007 Feb 1;
44(3):464-5.
Jiehui L, Marks SM, Driver CR, Diaz FA, Castro AF, de
Regner AF, Gibson AE, Dokubo-Okereke K, Munsiff SS, TB
Epidemiologic Studies Consortium. Human immunodeficiency
virus counseling, testing, and referral of close
contacts to patients with pulmonary TB: feasibility and
costs. J Public Health Management Practice 2007; 13(3):
252-62.
Katz D, Albalak R, Wing JS, Combs V, for the
Tuberculosis Epidemiologic Studies Consortium. Setting
the agenda: A new model for collaborative tuberculosis
epidemiologic research. Tuberculosis 2007; 87: 1-6.
Riekstina V, Leimane V, Holtz TH, Leimans J, Wells
CD. Treatment outcome cohort analysis in an integrated
DOTS and DOTS-Plus TB program in Latvia. International
Journal of Tuberculosis and Lung Disease May 2007;
11(5): 585-587.
Sable SB. Plikaytis BB. Shinnick TM. Tuberculosis
subunit vaccine development: impact of physicochemical
properties of mycobacterial test antigens. Vaccine Feb
19; 25(9):1553-66.
Thoen CO and LoBue PA. Mycobacterium bovis
tuberculosis: forgotten, but not gone [comment]. The
Lancet 2007 April 14; 369 (9569): 1236-1237.
Walton W. New activities and resources for engaging
all health care providers in TB elimination [editorial].
International Journal of Tuberculosis and Lung Disease
March 2007; 11 (3): 246.
Last Reviewed: 05/18/2008 Content Source: Division of Tuberculosis Elimination
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention
|